比较接受肿瘤坏死因子治疗的患者的 LTBI 治疗方案。

Comparison of LTBI treatment regimens for patients receiving anti-tumour necrosis factor therapy.

机构信息

Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.

Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.

出版信息

Int J Tuberc Lung Dis. 2015 Mar;19(3):342-8. doi: 10.5588/ijtld.14.0554.

DOI:10.5588/ijtld.14.0554

PMID:25686145

Abstract

SETTING

A tertiary referral centre in South Korea.

OBJECTIVE

To compare the completion rates and adverse drug reactions of three latent tuberculous infection (LTBI) treatment regimens for patients receiving anti-tumour necrosis factor (anti-TNF) therapy.

DESIGN

A total of 408 patients were diagnosed with LTBI before receiving anti-TNF therapy between December 2004 and December 2013. Nine months of isoniazid (9H), 4 months of rifampicin (4H) or 3 months of isoniazid/rifampicin (3HR) were prescribed. The results were analysed retrospectively.

RESULTS

The mean age of the 408 study subjects was 44 years; 258 (63.2%) were male. The 9H, 4R and 3HR treatment regimens were given to respectively 61 (15.0%), 139 (34.1%) and 208 (51.0%) patients. A total of 362 (88.7%) patients completed the treatment. The treatment completion rate was highest in patients receiving 3HR (94.2%). Of the 408 patients, 54 (13.2%) had one or more adverse drug reactions; their frequency was similar in the three groups.

CONCLUSIONS

In patients receiving anti-TNF therapy, 3HR seems to be the most acceptable treatment regimen for LTBI, given its high completion rate and acceptable rate of adverse drug reactions.

摘要

背景

韩国的一家三级转诊中心。

目的

比较三种潜伏性结核感染（LTBI）治疗方案在接受抗肿瘤坏死因子（anti-TNF）治疗的患者中的完成率和药物不良反应。

设计

共有 408 名患者在 2004 年 12 月至 2013 年 12 月期间接受抗 TNF 治疗前被诊断为 LTBI。方案为异烟肼 9 个月（9H）、利福平 4 个月（4H）或异烟肼/利福平 3 个月（3HR）。结果进行回顾性分析。

结果

408 名研究对象的平均年龄为 44 岁，258 名（63.2%）为男性。9H、4R 和 3HR 治疗方案分别给予 61 名（15.0%）、139 名（34.1%）和 208 名（51.0%）患者。共有 362 名（88.7%）患者完成了治疗。接受 3HR 治疗的患者治疗完成率最高（94.2%）。在 408 名患者中，54 名（13.2%）有一个或多个药物不良反应，三组不良反应的发生率相似。